Condition: Port-wine Birthmarks · Port-Wine Stain · Nevus Flammeus · Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
This description comes directly from the study's public registry record.
Xuejing Cheng · 00-86-021-58953355 · xjcheng@fd-zj.com
Always discuss trial participation with your own doctor first.
| UCI Health Beckman Laser Institute & Medical Clinic | Irvine, California, United States | Recruiting |
| Dermatology Cosmetic Associates of La Jolla, Inc. d/b/a West Dermatology Research Center | San Diego, California, United States | Recruiting |
| Miami Dermatology and Laser Institute | Miami, Florida, United States | Recruiting |
| Maryland Dermatology, Laser, Skin & Vein Institute | Hunt Valley, Maryland, United States | Recruiting |
| St. Luke's University Health Network | Bethlehem, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05171894